Add like
Add dislike
Add to saved papers

SECOND CANCER RISK FROM RADIATION THERAPY FOR COMMON SOLID TUMORS DIAGNOSED IN REPRODUCTIVE-AGED FEMALES.

This study provided second cancer risk estimates from radiation therapy for common solid tumors presented in reproductive-aged females. Three-dimensional treatment plans were generated for 10 patients with cervical, uterine, rectal, lung or breast carcinomas. The organ equivalent dose (OED) and the lifetime attributable risk (LAR) for carcinogenesis to organs receiving high doses were estimated for all study participants with a mechanistic model. This model accounts for cell-killing, tissue repair and dose fractionation effects. The patient- and organ-specific relative risk was assessed by using the LARs and the respective lifetime intrinsic cancer risks for unexposed population. The OED of the organs-at-risk varied from 17.3 to 1423.1 rad. The LAR range for bladder, colon, lung and breast cancer induction was 0.12-0.14%, 10.88-12.71%, 1.66-8.62% and 0.71-3.75%, respectively. The relative risk for the appearance of bladder, colon, lung and breast malignancies following radiotherapy was up to 1.12, 4.05, 2.42 and 1.31, respectively.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app